Ventricular fibrillation during coronary angiography with Renografin-76 (meglumine sodium diatrizoate) has been attributed to the calcium-binding additives sodium citrate and sodium ethylenediaminetetraacetic acid (EDTA), which may produce repolarization changes manifested as prolongation of the QT interval. Angiovist-370 is a newer form of meglumine sodium diatrizoate that contains calcium EDTA as its additive and thus has a decreased calcium-binding effect. Eight hundred sixteen patients were prospectively randomized to receive either Renografin-76 or Angiovist-370. Ventricular fibrillation occurred in to of 410 patients receiving Renografin-Ze and in 0 of 406 patients given Angiovist-370(p < 0.0005).
Clinical data were analyzed without knowledge of other data in the 10 patients treated with Renografin-76 who had ventricular fibrillation (Group I), 103 randomly selected patients who also received Renografm-76 but had no ventricular fibrillation (Group II) and 108 randomly selected patients given Angiovist-370 (Group III). Of several variables examined, only the QT interval differentiated patients receiving Renografin-76 and AnVentricular fibrillation during coronary angiography occurs in 0.6 to 1.3% of patients (1-5). It is unclear why some patients develop this potentially life-threatening complication of coronary angiography; however, it has been suggested that ventricular fibrillation during coronary angiography is a result of the electrophysiologic effects of the contrast media (6) (7) (8) (9) (10) (11) (12) (13) . Specifically, it has been observed that contrast agents cause a prolongation of repolarization giovist-370. The mean corrected QT interval (QT c interval) before coronary angiography was slightly but not significantly (p =0.7) higher in Group I than in Groups II and III. Ten seconds after the first left coronary artery injection it was more prolonged in Groups I and II (0.552 and 0.561 second, respectively) than in Group III (0.448 second) (p < 0.00005). Similarly, 10 seconds after the first right coronary artery injection it was significantly longer in Groups I and II (0.545 and 0.544 second) than in Group III (0.477 second) (p < 0.00005). The mean QT c interval after coronary angiography was slightly more prolonged in Groups I and II (0.469 and 0.455 second) compared with Group III (0.439 second) (p = 0.06).
Thus, the substitution of calcium EDTA in contrast agents significantly decreases the incidence of ventricular fibrillation during coronary angiography, perhaps by attenuating the repolarization changes (with resultant QT interval prolongation) induced by contrast agents.
(J Am Coli CardioI1987;10:1249-53) (with resultant QT interval prolongation) (13) . A proposed factor responsible for these repolarization changes has been the presence of the calcium-binding additives sodium citrate and sodium ethylenediaminetetraacetic acid (EDT A) found in Renografin-76, the most commonly used formulation of meglumine sodium diatrizoate (14) . Preclinical studies have found a reduced incidence of ventricular fibrillation during coronary angiography when using either calcium-enriched Renografin-76 (6) or a newer formulation of meglumine sodium diatrizoate, Angiovist-370 (15), which contains calcium EDT A as its additive, and thus has a reduced propensity to bind calcium. The purpose of this investigation was to prospectively determine whether the incidence of ventricular fibrillation during coronary angiography in humans could be reduced with a calcium-enriched contrast agent, and whether that reduced incidence of ventricular fibrillation could be correlated with changes in repolarization as measured by the QT interval. Data collection. Standard 6 lead electrocardiograms were recorded using an Electronics for Medicine or Honeywell Meddars paper recorder at 25 to 100 mmls paper speed. Electrocardiograms were obtained before the catheterization, up to 10 seconds after the first left and right coronary artery injections and within 5 minutes of completion of the catheterization.
Clinical characteristics, heart rate and QT intervals were obtained for all 10 patients who had ventricular fibrillation during coronary angiography (Group I) . Similar variables were measured in every fourth patient selected at random for subgroup analysis. This included 103 patients receiving Renografin-76 (Group II) and 108 patients studied with Angiovist-370 (Group 1II).
QT intervals from each electrocardiogram were measured by one of three investigators who did not know which contrast agent was used. T wave termination was taken as the transection of the baseline with a line parallel to the rapidly descending portion of the T wave; U waves were excluded. The longest QT interval in any standard lead was used and corrected for heart rate by Bazett's formula: QT QT c
• r.:;-;:: (16) .
vRR Statistical analysis. Ventricular fibrillation incidence rates were compared using a chi-square analysis. Clinical characteristics, heart rate and QT intervals were analyzed by two factor analysis of variance , followed by simple main effects analysis and Tukey-A post hoc tests. Results were considered significantly different when p < 0.05. (27 ) 20 ( .. II) and 108 patients given Angiovist-370 (Group III) are shown in Table I . There were no significant differences among the groups with respect to age. sex. history of previous myocardial infarction, history of prior ventricular tachycardia or ventricular fibrillation , or current medications. A very small percentage of patients were taking type I antiarrhythmic drugs, and none were taking type III antiarrhythmic agents. The groups were also similar with regard to severity of coronary artery disease and left ventricular function. Serum potassium in Groups I. II and III was 4. 1 ± 0.1, 4.2 ± 0.04 and 4.1 ± 0.04 mEqlliter, respectively. QT intervals. The mean QT c interval ± SEM within each group is shown in Figure I . Before coronary angiography the QT c interval was longer in Group I than in Groups II and Ill. but this difference did not reach statistical significance (p = 0.7). After initial left and right coronary artery injections, there was less marked QT c prolongation in Group III (Angiovist-370) than in Groups I and II (Renografi n-76) (p < 0.00005). After angiography the QT t . interval remained somewhat more prolonged in both groups receiving Renografin-76 (Groups I and II) than in patients receiving Angiovist-370 (Group III). at a borderline statistical level (p = 0.06). The mean heart rate was not significantly different among the three groups throughout the cardiac catheterization (Table 2 ).
Discussion
Myocardial effects of contrast agents. Contrast agents used in coronary arteriography are responsible for profound alterations in cardiac function, including changes in heart rate. blood pressure, peripheral resistance, coronary blood flow, myocardial contractility and blood chemistry (17-2 1). In addition, electrocardiographic changes have been identified, and include QRS and T wave axis shifts, bradycardia and QT interval prolongation with the latter being linked to contrast media-induced ventricular fibrillation (5, (22) (23) (24) (25) (26) . These changes in repolarization, as reflected by QT t . prolongation, may contribute to an increased incidence of ventricular fibrill ation by producing an increased dispersion of repolarization (27) . Murdock et al. (13) postulated that with a decrease in QT t prolongation there is a resultant decrease in conduction delay of premature ventricular beats, and therefore sufficient delay to achieve reentry is no longer possible.
Initial attempts to decrease the incidence of ventricular fibrillation during coronary angiography focused on the sodium content of contrast agents. A series of experiments (11,18,28-30) identified an ideal concentration of sodium; a lower concentration resulted in prolonged depolarization and a higher concentration in prolongedrepolarization, both of which produced an increased incidence of ventricular fibrillation.
Role of calcium. Calcium flux has also been investigated for its role in the genesis of ventricularfibrillation. Caulfield et al. (31) observed a decrease in ionized serum calcium levels in blood collected from the coronary sinus immediately after coronary artery injection of Renografin-76. They attributedthe decreaseof the ionizedcalciumto the chelating action of sodium citrate and sodium EDTA, which are contained in Renografin-76 as stabilizing agents. This finding was further supported by Thomson et al. (6) , who demonstrated a lower incidenceof ventricularfibrillation in dogs given a calcium-enriched formulation rather than the standard formulation of Renografin-76. More recently, a decreased incidence of ventricular fibrillation in dogs was shown (15) using a newer formulation of meglumine sodium diatrizoate, Angiovist-370, that contains as its additivecalcium EDTA, which has less calcium-binding activity than the additives found in Renografin-76. In addition, Murdock et al. (15) found less QT interval prolongation with Angiovist-370 than with Renografin-76. In the only prospective study performed in humans, Wolf and Hirschfeld (14) examined the changes in QT intervals in four patients receiving either Renografin-76 or Hypaque-76 (Winthrop Laboratories), a contrast agent similar to Angiovist-370, which also contains calcium EDTA as its additive. They found less QT interval prolongation with Hypaque-76 and suggested that contrast agents with reduced calcium-binding properties may produce less ventricular fibrillation during coronary angiography. Their study was limited by inclusionof a very small number of patients.
Present study. We prospectively examined the role of calcium-binding additives on ventricular fibrillation during coronary angiography in 816 patients. Several clinical and electrocardiographic characteristics were also analyzed in a randomly selected subset of those patients. We found a marked reduction in the incidence of ventricular fibrillation when using Angiovist-370 (calcium EDTA as additive) as compared with Renografin-76 (sodium citrate and sodium EDTA as additives). Patients receiving Angiovist-370 had significantly less QT interval prolongation during coronary artery injections as compared with patients receiving Renografin-76. These results indicate that the incidence of ventricular fibrillation during coronary angiography, as well as QT c prolongation (14) , can be reduced by eliminating the calcium-binding additives found in contrast agents.
Our study also suggests that baseline repolarization abnormalities may contribute to the incidence of ventricular fibrillation. The QT interval before coronary angiography was higher in Group I (ventricular fibrillation) than in Groups II and III (Renografin-76 and Angiovist-370 without ventricular fibrillation). While this difference is not statistically significant, it supports previously published data (32) in a larger group of patients with ventricularfibrillation in whom QT interval prolongation before angiography was found to be an importantrisk factorfor the developmentof ventricular fibrillation.
Study limitations. Our study is limited by the fact that comparisons were made between patients with ventricular fibrillation (Group I) and a random sample of the patients receiving Renografin-76 (Group II) and Angiovist-370 (Group III) who were arrhythmia free. This limitation is mitigated by the apparent similarity of the three groups with respect to clinical characteristics and extent of coronary disease. An additional limitation is that QT interval measurements are subject to interobserver and intraobserver variations (33) . Our study provided for a blinded analysis of the data, which partially obviates that bias. Nonionic contrast agents were not evaluatedin our study, but they also reduce the incidence of ventricular fibrillation when comparedwith ionic contrast agents (8, 9, 17) . Calcium-enriched forms of meglumine sodium diatrizoate, which are comparably priced with similar contrast mediausing sodium EDTA as their additive, appear to be more reasonable alternative contrast agents in view of their markedly reduced incidence of ventricular fibrillation. Finallyother factors, such as quantity of contrast agent used with each coronary injection, as well as changes in conduction and automaticity, were not analyzed but may be as important as repolarization abnormalities in the genesis of ventricular fibrillation during coronary angiography.
